Reading DMRA? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track DMRA free→DAMORA THERAPEUTICS INC (DMRA)
NASDAQHealth CareBiotechnologySnapshot 2026-07-02
$29.98+10.67%
Close 2026-07-02 · 1-day change
The bottom line
The thesis is that DMRA's growth will depend on the Healthcare sector's performance. If sector leaders like VRTX and REGN keep beating earnings, DMRA could benefit. Revenue growth has been weak, and there is no recent earnings release to assess. DMRA trades at a premium compared to its peers, which raises concerns. If sector bellwethers start missing earnings, that could hurt DMRA significantly. Peer multiples imply a price about 12% above where it trades. This read is provisional.
as of 2026-07-02
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Biotechnology
- Market cap
- $1.85B
- Employees
- —
- IPO date
- 2020-10-07
- Next earnings
- 2026-08-04
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 0 valuation methods, at three horizons. Current price $29.98. As of 2026-07-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Fair value· primary
—
Range — – —
vs price: —
Method agreement —
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
3-year
—consensus
Range — – —
vs price: —
Method agreement —
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
5-year
—consensus
Range — – —
vs price: —
Method agreement —
A long-thesis check that carries the widest uncertainty of the three horizons.
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
12-month view
Not enough valuation methods to set a 12-month read yet.
Compared to peers
Not enough peers to compare yet.
Compared to its own history
Self-history needs ~20 months of data.
P/E
—
EV/EBITDA
—
FCF yield
—
Earnings yield (TTM)
Long-term · 1–3 yrHow strong is the business
(quality & execution)Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): mixed.Secular epoch: Mature by revenue growth · theme AI-drug-discovery.neutral-1.0%sector vs S&P 500, 60d
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
AI cycle regime · market-wide
2-axis classifierLong-term · 1–3 yr
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Scorecard refreshing. Check back after the next snapshot.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Long-term · 1–3 yr
No qualifying priorities for this snapshot. Check back after the next refresh.
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$290.
How much price usually moves either way.
On a bad day, this stock has moved -$1,287.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,238.
Deepest peak-to-trough drop in the last year.
—as of 2026-07-02
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-02
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for DMRA yet.
This sector is also watching
- Watch for Health Care revenue growth to re-accelerate above 10%
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
No upside scenarios in the latest snapshot.
Downside triggers
No downside scenarios in the latest snapshot.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
No material events in the last 90 days.
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.